Revolution Medicines, Inc. (RVMDW) Return on equity 2020–2025
Revolution Medicines, Inc. (RVMDW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-69.3%FY2025 · since FY2020: -22.8% → -69.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -69.3% | -42.9 pp |
| FY2024 | -26.5% | -2.6 pp |
| FY2023 | -23.9% | +12.4 pp |
| FY2022 | -36.3% | -5.2 pp |
| FY2021 | -31.0% | -8.3 pp |
| FY2020 | -22.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RVMDW financial trends
RVMDW RevenueRVMDW Net incomeRVMDW Net marginRVMDW Gross profitRVMDW Gross marginRVMDW Operating incomeRVMDW Operating marginRVMDW Operating cash flowRVMDW Free cash flowRVMDW Capital expendituresRVMDW Stock buybacksRVMDW Dividends paidRVMDW Total assetsRVMDW Total liabilitiesRVMDW Shareholders’ equityRVMDW overview →